A Phase 1 Study To Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Lorlatinib (Primary)
- Indications Brain metastases; Glioma; Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 11 Oct 2019 Planned End Date changed from 24 Sep 2022 to 25 Jan 2023.
- 11 Oct 2019 Planned primary completion date changed from 15 Apr 2022 to 16 Aug 2022.
- 11 Oct 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 30 Aug 2019 to 31 Dec 2019.